

Helen Cox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5524786/publications.pdf>

Version: 2024-02-01

99
papers

7,058
citations

76326

40
h-index

60623

81
g-index

105
all docs

105
docs citations

105
times ranked

6878
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Response in Pediatric Pulmonary Tuberculosis—A Prospective Longitudinal Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 329-336.	1.3	1
2	Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0236221.	3.9	14
3	Oral Swab Specimens Tested With Xpert MTB/RIF Ultra Assay for Diagnosis of Pulmonary Tuberculosis in Children: A Diagnostic Accuracy Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 2145-2152.	5.8	20
4	“We had to manage what we had on hand, in whatever way we could”: adaptive responses in policy for decentralized drug-resistant tuberculosis care in South Africa. <i>Health Policy and Planning</i> , 2021, 36, 249-259.	2.7	5
5	Building resilience needs to be central to treating drug-resistant tuberculosis. <i>The Lancet Global Health</i> , 2021, 9, e381-e382.	6.3	1
6	Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0036421.	3.2	7
7	Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. <i>Lancet Microbe</i> , The, 2021, 2, e584-e593.	7.3	9
8	The incalculable costs of tuberculosis. <i>The Lancet Global Health</i> , 2021, 9, e1337-e1338.	6.3	0
9	“This is not my body”: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis. <i>PLoS ONE</i> , 2021, 16, e0251482.	2.5	8
10	Preventing drug-resistant tuberculosis transmission. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 157-158.	9.1	5
11	Correspondence regarding “Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa”. <i>European Respiratory Journal</i> , 2020, 56, 2000837.	6.7	2
12	HIV Coinfection Is Associated with Low-Fitness <i>rpoB</i> Variants in Rifampicin-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
13	“A very humiliating illness”: a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. <i>BMC Public Health</i> , 2020, 20, 76.	2.9	34
14	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	6.3	53
15	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet</i> , The, 2019, 393, 1331-1384.	13.7	257
16	Tuberculosis. <i>Lancet</i> , The, 2019, 393, 1642-1656.	13.7	523
17	The STREAM trial: missed opportunities and lessons for future clinical trials. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 351-353.	9.1	9
18	Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 298-307.	9.1	45

#	ARTICLE	IF	CITATIONS
19	Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 536-544.	9.1	106
20	Tuberculosis eradication: renewed commitment and global investment required. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 228-229.	9.1	9
21	Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. <i>European Respiratory Journal</i> , 2018, 51, 1800017.	6.7	39
22	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 265-275.	10.7	80
23	Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e282-e287.	9.1	35
24	Recent controversies about <scp>MDR</scp> and <scp>XDRâ€TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDRâ€TB</scp> regimen and bedaquiline for all with <scp>MDRâ€TB</scp>?. <i>Respirology</i> , 2018, 23, 36-45.	2.3	52
25	The Coming of Age of Drug-Susceptibility Testing for Tuberculosis. <i>New England Journal of Medicine</i> , 2018, 379, 1474-1475.	27.0	15
26	Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. <i>Current Opinion in Pharmacology</i> , 2018, 42, 7-15.	3.5	121
27	Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia. <i>ELife</i> , 2018, 7, .	6.0	93
28	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2017, 49, 1600993.	6.7	20
29	Prevention of hearing loss in patients with multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2017, 390, 934.	13.7	4
30	Epidemiology of Drug-Resistant Tuberculosis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1019, 209-220.	1.6	32
31	Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002238.	8.4	81
32	Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, S238-S243.	5.8	60
33	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	6.7	27
34	Outbreak of multidrug-resistant tuberculosis on Daru Island. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 347-349.	10.7	17
35	Multidrug-Resistant TB: Implementing the Right to Health through the Right to Enjoy the Benefits of Scientific Progress. <i>Health and Human Rights</i> , 2016, 18, 25-41.	1.3	10
36	Cost per patient of treatment for rifampicinâ€resistant tuberculosis in a communityâ€based programme in Khayelitsha, South Africa. <i>Tropical Medicine and International Health</i> , 2015, 20, 1337-1345.	2.3	31

#	ARTICLE	IF	CITATIONS
37	Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 172-178.	1.2	48
38	Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa. <i>PLoS ONE</i> , 2015, 10, e0118919.	2.5	26
39	Compassionate and optimum use of new tuberculosis drugs. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1131.	9.1	15
40	Evolutionary history and global spread of the <i>Mycobacterium tuberculosis</i> Beijing lineage. <i>Nature Genetics</i> , 2015, 47, 242-249.	21.4	466
41	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. <i>The Lancet Global Health</i> , 2015, 3, e450-e457.	6.3	179
42	Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 425-432.	1.8	20
43	Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. <i>International Journal of Infectious Diseases</i> , 2015, 32, 56-60.	3.3	36
44	Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. <i>European Respiratory Journal</i> , 2015, 46, 271-274.	6.7	24
45	In reply. QTc prolongation and delamanid: access and safety. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1262-1263.	1.2	0
46	QTc prolongation and treatment of multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 385-391.	1.2	46
47	A systematic review and meta-analysis of the efficacy and safety of <i>N</i> -acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. <i>Thorax</i> , 2015, 70, 1070-1077.	5.6	54
48	Linezolid in drug-resistant tuberculosis: haste makes waste. <i>European Respiratory Journal</i> , 2015, 46, 1844-1846.	6.7	3
49	Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1513-1519.	1.2	41
50	Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success. <i>PLoS ONE</i> , 2015, 10, e0142873.	2.5	12
51	The need to accelerate access to new drugs for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2015, 93, 491-497.	3.3	14
52	The scourge of tuberculosis and anti-tuberculosis drug resistance in Eastern Europe. <i>Public Health Action</i> , 2014, 4, 1-2.	1.2	2
53	Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial. <i>PLoS Medicine</i> , 2014, 11, e1001760.	8.4	118
54	Better treatment of XDR tuberculosis needed in South Africa. <i>Lancet</i> , The, 2014, 384, 581-582.	13.7	1

#	ARTICLE	IF	CITATIONS
55	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
56	Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 441-448.	1.2	89
57	The benefits and risks of mathematical modelling in tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 507-507.	1.2	4
58	Outcomes in Adolescents Undergoing Treatment for Drug-resistant Tuberculosis in Cape Town, South Africa, 2008-2013. <i>Archives of Pediatric Infectious Diseases</i> , 2014, 2, .	0.3	7
59	Decentralisation of multidrug-resistant-tuberculosis care and management. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 644-646.	9.1	12
60	Linezolid for multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 16.	9.1	7
61	Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 299-307.	1.2	119
62	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 529-539.	9.1	243
63	Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 284-293.	3.0	116
64	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	6.7	346
65	Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1676-1684.	5.8	101
66	First Molecular Epidemiology Study of Mycobacterium tuberculosis in Kiribati. <i>PLoS ONE</i> , 2013, 8, e55423.	2.5	16
67	Whole Genome Sequencing Reveals Complex Evolution Patterns of Multidrug-Resistant Mycobacterium tuberculosis Beijing Strains in Patients. <i>PLoS ONE</i> , 2013, 8, e82551.	2.5	117
68	Population Structure of Mixed Mycobacterium tuberculosis Infection Is Strain Genotype and Culture Medium Dependent. <i>PLoS ONE</i> , 2013, 8, e70178.	2.5	57
69	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
70	Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 447-454.	1.2	123
71	Sanatoria for drug-resistant tuberculosis: an outdated response. <i>Lancet</i> , The, 2012, 379, 2148.	13.7	6
72	MDR tuberculosis and non-compliance with therapy. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 178.	9.1	2

#	ARTICLE	IF	CITATIONS
73	Moxifloxacin for tuberculosis – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 177-178.	9.1	2
74	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. <i>Journal of Infectious Diseases</i> , 2012, 205, S147-S158.	4.0	154
75	Drug-Resistant Tuberculosis – Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. <i>Journal of Infectious Diseases</i> , 2012, 205, S228-S240.	4.0	140
76	Wind-Driven Roof Turbines: A Novel Way to Improve Ventilation for TB Infection Control in Health Facilities. <i>PLoS ONE</i> , 2012, 7, e29589.	2.5	27
77	Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. <i>PLoS ONE</i> , 2012, 7, e40781.	2.5	80
78	Rational use of moxifloxacin for tuberculosis treatment. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 259-260.	9.1	11
79	Household screening and multidrug-resistant tuberculosis. <i>Lancet</i> , The, 2011, 377, 103-104.	13.7	4
80	Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. <i>Lancet</i> , The, 2011, 377, 1495-1505.	13.7	902
81	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. <i>PLoS ONE</i> , 2011, 6, e28066.	2.5	71
82	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. <i>BMC Infectious Diseases</i> , 2010, 10, 83.	2.9	24
83	Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa. <i>PLoS ONE</i> , 2010, 5, e13901.	2.5	71
84	embCAB sequence variation among ethambutol-resistant <i>Mycobacterium tuberculosis</i> isolates without embB306 mutation. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1359-1367.	3.0	76
85	Extensively drug-resistant tuberculosis in South Africa. <i>Lancet</i> , The, 2010, 376, 681.	13.7	2
86	Tuberculosis trends in the Pacific: 2000-2006. <i>Pacific Health Dialog: A Publication of the Pacific Basin Officers Training Program and the Fiji School of Medicine</i> , 2010, 16, 157-71.	0.2	3
87	Tuberculosis ethambutol resistance: Concordance between phenotypic and genotypic test results. <i>Tuberculosis</i> , 2009, 89, 448-452.	1.9	30
88	Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> Strains in Multidrug-Resistant Tuberculosis Patients Undergoing Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3353-3356.	3.2	88
89	Are we really that good at treating tuberculosis?. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 138-139.	9.1	10
90	Genomic Diversity among Drug Sensitive and Multidrug Resistant Isolates of <i>Mycobacterium tuberculosis</i> with Identical DNA Fingerprints. <i>PLoS ONE</i> , 2009, 4, e7407.	2.5	128

#	ARTICLE	IF	CITATIONS
91	XDR tuberculosis can be cured with aggressive treatment. <i>Lancet, The</i> , 2008, 372, 1363-1365.	13.7	8
92	Emergence of Extensive Drug Resistance during Treatment for Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2008, 359, 2398-2400.	27.0	57
93	Risk of Acquired Drug Resistance during Short-Course Directly Observed Treatment of Tuberculosis in an Area with High Levels of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2007, 44, 1421-1427.	5.8	68
94	Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures. <i>PLoS ONE</i> , 2007, 2, e1126.	2.5	84
95	Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance. <i>PLoS Medicine</i> , 2006, 3, e384.	8.4	100
96	To treat or not to treat? Implementation of DOTS in Central Asia. <i>Lancet, The</i> , 2003, 361, 714-715.	13.7	4
97	Effect of multidrug resistance on global tuberculosis control. <i>Lancet, The</i> , 2003, 362, 1858-1859.	13.7	15
98	Mineralocorticoid Induced Hypertension and Noradrenaline Spillover In Man. <i>Clinical and Experimental Hypertension</i> , 1994, 16, 147-161.	1.3	13
99	Monoaminergic Neuronal Activity in Subcortical Brain Regions in Essential Hypertension. <i>Blood Pressure</i> , 1994, 3, 55-66.	1.5	31